国金证券给予安图生物买入评级，国内市场短期承压，新领域拓展成果丰富

Group 1 - The core viewpoint of the report is that Guotai Junan Securities has given Antu Biology (603658.SH) a "buy" rating based on its market performance and growth potential [2] - The report highlights that the domestic market is currently under pressure, but Antu Biology is expected to consolidate and increase its market share [2] - Continuous high investment in research and development is anticipated to contribute to long-term growth as the company explores new fields [2]